CagriSema
Cagrilintide/Semaglutide
A fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, studied in phase 3 trials for weight management and for glycemic control in type 2 diabetes. Both components are given on a weekly schedule. Not approved.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
About one week for both components, consistent with the weekly schedule used in trials. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Investigational; no approved label defines handling.
References
- NEJM 2025: coadministered cagrilintide and semaglutide in adults with overweight or obesity
- NEJM 2025: cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.